Opioid Dependence
Conditions
Keywords
Opioid dependence, Suboxone, addiction, BEMA Buprenorphine NX, oral transmucosal
Brief summary
This is an open label study in opioid dependent subjects maintained on a stabilized dose of Suboxone tablets or films. The purpose is to assess the safety and tolerability of BEMA Buprenorphine NX administered once daily for 12 weeks to opioid dependent subjects stabilized on Suboxone (buprenorphine/naloxone) tablets or films. Eligible subjects will be converted to an approximately equal dose of BEMA Buprenorphine NX. This dose will be taken throughout the 12-week treatment period with dose adjustments as clinically indicated for either the control of opioid dependence or adverse events (AEs).
Detailed description
This is an open label study in opioid dependent subjects maintained on a stabilized dose of Suboxone tablets or films. Eligible subjects will be converted to an approximately equal dose of BEMA Buprenorphine NX. This dose will be taken throughout the 12-week treatment period with dose adjustments as clinically indicated for either the control of opioid dependence or adverse events (AEs). Subjects will be monitored for evidence of buccal irritation attributed to the application of the BEMA Buprenorphine NX film and opioid dependence control according to the Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction - A Treatment Improvement Protocol (TIP 40) guidelines for the use of buprenorphine in the management of opioid dependence. The total duration of participation for each subject will be up to approximately 18 weeks and includes a Screening period (subjects continue to take Suboxone tablets or films), Baseline visit, a 12-week open label treatment period (subjects take BEMA Buprenorphine NX films and at the Day 84 visit, subjects will return to their prior Suboxone treatment), and a Follow-up Visit. Vital signs, pulse oximetry, opioid withdrawal symptoms, adverse events (AEs), oral examinations, and concomitant medications will be assessed at intervals throughout the study. Clinical laboratory assessments, urine toxicology and buprenorphine testing, and 12-lead electrocardiograms (ECGs) will also be performed.
Interventions
DRUGBEMA Buprenorphine NX films
BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
Sponsors
BioDelivery Sciences International
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Written informed consent obtained at Screening, prior to any study procedure being performed 2. Male or non-pregnant and non-nursing female. A female of childbearing potential is eligible to participate in this study if she is not pregnant, and is using an acceptable method of birth control 3. Subject is aged 18 to 65 years of age, inclusive 4. Diagnosis of opioid dependence per the Diagnostic and Statistical Manual of Mental Disorders - 4th edition (text revision) (DSM-IV-TR) criteria in the past 12 months including physical dependence on opioids and addiction with compulsive use despite harm 5. Currently taking a stable, single daily dose of 16/4 to 32/8 mg Suboxone tablets or films (buprenorphine/naloxone) for at least 30 days 6. Subject is in good general health; with no clinically significant findings on medical history, physical examination, safety laboratory test and ECG in the judgment of the investigator at screening. Serum creatinine, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) values must be within 3-times the upper limit of normal (ULN). Pulse oximetry must be ≥96%, systolic blood pressure ≥110 mmHg, and diastolic blood pressure ≥65 mmHg.
Exclusion criteria
1. Hypokalemia, hypomagnesemia, or clinically unstable cardiac disease, including: unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, active myocardial ischemia, or clinically significant arrhythmias 2. History of Long QT Syndrome, or an immediate family member with this condition 3. Currently taking Class IA antiarrhythmic medications (eg, quinidine, procainamide, disopyramide) or Class III antiarrhythmic medications (eg, sotalol, amiodarone, dofetilide) 4. Uncontrolled hypertension defined as systolic blood pressure \>170 mmHg and diastolic blood pressure \>90 mmHg at Baseline 5. Pulse oximetry ≤93% at Baseline, regardless of cause 6. Clinically significant abnormality on 12-lead ECG, including a QTc interval \>490 milliseconds 7. Use of any medication, nutraceutical or herbal product with CYP3A4 inhibition or induction properties within the past 30 days (see Appendix 4 for a list of applicable drugs). This exclusion also extends to grapefruit juice and grapefruit juice-containing products as well as St. John's wort and St. John's wort-containing products (prescription or nonprescription drugs, vitamins, minerals, or dietary/herbal supplements). 8. Diagnosis of moderate to severe hepatic impairment 9. Use of an investigational drug or device within the last 30 days 10. Participation in a previous clinical study of BEMA Buprenorphine NX or BEMA Buprenorphine 11. History of hypersensitivity, allergy, or intolerance to buprenorphine, naloxone, or related drugs 12. Pierced tongue or mouth 13. Any clinically significant abnormality of the buccal mucosa which could impact drug absorption 14. Suicidal risk, as determined by meeting any of the following: 1. History of suicidal ideation ≤ 3 months prior to Baseline with a score of 4 (intent to act) or 5 (specific plan and intent) on the eC-SSRS 2. History of suicidal behavior ≤ 1 year prior to Baseline (actual attempt, interrupted attempt, aborted attempt and/or preparatory acts/behavior) on the eC-SSRS 15. A history or current evidence of any clinically significant disorder or any other condition which in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | 12 weeks | Adverse events that occur in more than 2 subjects. Among the adverse events that occurred in \> 2 subjects, the total number of unique events that were experienced are reported. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Urine Drug Screen | 12 weeks | Urine samples collected at screening and baseline to test for the presence of non-prescribed opioids. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| BEMA Buprenorphine NX Films BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone)will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
BEMA Buprenorphine NX films: BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively. | 249 |
| Total | 249 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 6 |
| Overall Study | Lost to Follow-up | 7 |
| Overall Study | non compliance with study medication, pa | 18 |
| Overall Study | Subject experiencing withdrawal symptoms | 5 |
| Overall Study | Withdrawal by Subject | 16 |
Baseline characteristics
| Characteristic | BEMA Buprenorphine NX Films |
|---|---|
| Age, Continuous | 38.7 years STANDARD_DEVIATION 10.2 |
| Region of Enrollment United States | 249 participants |
| Sex: Female, Male Female | 85 Participants |
| Sex: Female, Male Male | 164 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 89 / 249 |
| serious Total, serious adverse events | 1 / 249 |
Outcome results
Primary
Adverse Events
Adverse events that occur in more than 2 subjects. Among the adverse events that occurred in \> 2 subjects, the total number of unique events that were experienced are reported.
Time frame: 12 weeks
Population: All subjects who received at least 1 dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| BEMA Buprenorphine/NX Films | Adverse Events | 36 adverse events |
Secondary
Urine Drug Screen
Urine samples collected at screening and baseline to test for the presence of non-prescribed opioids.
Time frame: 12 weeks
Population: Subjects with at least one urine drug screen test during the treatment period.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| BEMA Buprenorphine/NX Films | Urine Drug Screen | Subjects with +-result for non-prescribed opiod | 19 participants |
| BEMA Buprenorphine/NX Films | Urine Drug Screen | Number with single positive result | 11 participants |
| BEMA Buprenorphine/NX Films | Urine Drug Screen | Number with 2 positive results | 4 participants |
| BEMA Buprenorphine/NX Films | Urine Drug Screen | Number with > 2 positive results | 4 participants |